{"filing":{"accession_number":"0001193125-26-401010","cik":"0002114044","ticker":"COAG","company_name":"Hemab Therapeutics Holdings, Inc.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"d35700d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526401010/d35700d8k.htm"},"events":[{"id":34860,"run_id":32098,"accession_number":"0001193125-26-401010","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the election of Keli Walbert to the Board of Directors as a Class I director effective immediately, with appointment to the Audit Committee. While the disclosure includes compensatory arrangements (equity option grant and annual cash compensation), the principal disclosed action is the appointment of a new director to the Board and a Board committee, making exec_appointment the most salient classification. Board composition changes are material to investors.","company_name":"Hemab Therapeutics Holdings, Inc.","ticker":"COAG","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38714,"accession_number":"0001193125-26-401010","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the election of Keli Walbert to the Board of Directors as a Class I director effective immediately, with appointment to the Audit Committee. While the disclosure includes compensatory arrangements (equity option grant and annual cash compensation), the principal disclosed action is the appointment of a new director to the Board and a Board committee, making exec_appointment the most salient classification. Board composition changes are material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:05:52.952002+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38714,"accession_number":"0001193125-26-401010","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the election of Keli Walbert to the Board of Directors as a Class I director effective immediately, with appointment to the Audit Committee. While the disclosure includes compensatory arrangements (equity option grant and annual cash compensation), the principal disclosed action is the appointment of a new director to the Board and a Board committee, making exec_appointment the most salient classification. Board composition changes are material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T20:05:52.952002+00:00","company_name":"Hemab Therapeutics Holdings, Inc.","ticker":"COAG","filing_date":"2026-09-24"}]}